title: CD10 is a diagnostic and prognostic marker in renal malignancies.
abstract: OBJECTIVE
  To determine the diagnostic and prognostic value of CD10 immunoreactivity in renal cell carcinomas (RCCs) and transitional cell carcinomas (TCCs).
  
  
  RESULTS
  CD10 expression was investigated in primary (n = 180) and metastatic (n = 58) RCCs and upper urinary tract TCCs (n = 53) using a tissue microarray technique. One hundred and fifty-four of 172 (90%) evaluable primary and 48/56 (86%) evaluable metastatic RCCs expressed CD10. Extensive immunoreactivity (positivity of >50% cancer cells) decreased with rising tumour grade in conventional RCCs [G1/G2 72/81 (89%), G3/G4 33/48 (69%); P = 0.009]. Chromophobe RCCs showed a significantly lower overall and extensive immunoreactivity compared with conventional tumours (P < 0.001). In papillary RCCs immunoreactivity of more than 10% of cancer cells for CD10 was seen more often in type 2 (7/8, 88%) compared with type 1 (5/12, 42%; P =0.054) tumours. In conventional RCCs, pure apical membranous staining was associated with low tumour stage (P = 0.003), low grade (P = 0.004) and improved prognosis on univariate analysis (P = 0.031). TCCs were less frequently stained (51%). Extensive staining, however, was associated with high-stage tumours (P = 0.024), high-grade (P = 0.073) tumours, and was associated with shorter disease-free survival in univariate analysis (P = 0.003).
  
  
  CONCLUSIONS
  CD10 proved to be an additional marker for renal malignancies with predominantly diagnostic potential.
authors.affiliation: Institute of Pathology, Department of Surgery, Division of Biomedical Engineering & Computing, University of Graz, Medical School, Graz, Austria. cord.langner@meduni-graz.at
authors.forename: C
authors.initials: C
authors.lastname: Langner
authors.forename: M
authors.initials: M
authors.lastname: Ratschek
authors.forename: P
authors.initials: P
authors.lastname: Rehak
authors.forename: L
authors.initials: L
authors.lastname: Schips
authors.forename: R
authors.initials: R
authors.lastname: Zigeuner
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000473:pathology; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis / Q000473:pathology; D005260:Female; D006801:Humans; D007668:Kidney / Q000166:cytology; D007680:Kidney Neoplasms / Q000175:diagnosis* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015260:Neprilysin; D011379:Prognosis; D013534:Survival
chemical_list: D015415:Biomarkers; D015260:Neprilysin